- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Synthekine Inc.
Headquarters: Menlo Park, CA, United States
Website: https://www.synthekine.com
Year Founded: 2018
Status: Private
BioCentury | Feb 21, 2024
Management Tracks
Papa succeeds Miller as Emergent’s CEO
Plus: Paratus names Heah as CEO and updates from Jazz, Arvinas, KaliVir, Celcuity, QuidelOrtho, Turnstone and PhRMA
BioCentury | Feb 6, 2024
Deals
Deals roundup: Novo boosts obesity manufacturing with Catalent buy
BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5
BioCentury | Apr 6, 2023
Finance
Canaan’s latest fund smaller than last, reflecting ‘recalibration’ in response to market
$650M thirteenth fund is accompanied by separate $200M vehicle to back existing portfolio companies
BioCentury | Mar 24, 2023
Product Development
Landscape of emerging T cell therapies in cancer
Four axes of risk map how companies founded in the last five years are innovating in CAR T and TCR T cells
BioCentury | Jan 26, 2023
Management Tracks
Juvena hires three new senior executives
Plus: new CEO at ClostraBio, and updates from Cambrian and Pliant
BioCentury | Jan 7, 2023
Deals
Jan. 6 Quick Takes: Pfizer ‘externalizing’ some cancer, rare disease programs
Plus: Column Group leads Synthekine’s $100M series C, and updates from Amolyt, Perceive, bluebird bio, BioNTech and more
BioCentury | Mar 25, 2022
Discovery & Translation
AACR22 tackles the CAR T solid tumor challenge
Dual-targeting CARs, new targets and bispecific adaptors among the top innovations
BioCentury | Mar 19, 2022
Discovery & Translation
A computationally designed IL-2; plus Adimab/Mapp, Kahr and more
BioCentury’s roundup of translational news
BioCentury | Mar 18, 2022
Product Development
The IL-2 cancer pipeline remains deep, diverse
There’s still hope for ‘not-alpha’ IL-2 therapies after Nektar’s Ph III failure, with a pipeline full of diverse modalities and MOAs
BioCentury | Jan 29, 2022
Product Development
Simcha pressure-testing engineered IL-18 with $40 million series B
Founded by Aaron Ring, Yale spinout is exploring its lead candidate’s potential as a cancer monotherapy while building out its management team
Items per page:
1 - 10 of 16